5. Kortte KB, Horner MD, Windham WK. The Trail Making Test, Part B: cognitive Flexibility or Ability to Maintain Set? Appl Neuropsychol 2002;9:106-109.
6. Fucetola R, Seidman LJ, Kremen WS, Faraone SV, Goldstein JM, Tsuang MT. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 2000;48:137-146.
7. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000;401:3-38.
8. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 1999;60:25-28.
9. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 1997;25:1-10.
10. Cuesta MJ, Peralta V, Zarzuela A. Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res 1998;33:141-150.
11. Kalwa A, Rzewuska M, Borkowska A. Cognitive dysfunction progression in schizophrenia-Relation to functional and clinical outcome. Arch Psychiatry Psychother 2012;1:5-13.
12. Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry 2009;195:286-293.
14. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms and Commentary. 2nd Ed. New York: Oxford University Press; 1998.
15. Mitrushina M, Boone KB, Razani J, D’Elia LF. Handbook of Normative Data for Neuropsychological Assessment. 2nd Ed. New York: Oxford University Press; 2005.
16. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20:145-151.
17. Herman M. Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. Int J Ment Health Nurs 2004;13:282-291.
18. Cooper L, Liberman D, Tucker D, Neuchterlein KH, Tsuang J, Barnett HL. Neurocognitive deficits in the dually diagnosed with schizophrenia and cocaine abuse. Psychiatr Rehabil Skill 1999;3:231-245.
19. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003;28:48-54.
21. Burdick KE, Goldberg JF, Harrow M, Faull RN, Malhotra AK. Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis 2006;194:255-260.
23. Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D, et al. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry 1993;150:1355-1362.
27. Martínez-Arán A, Penadés R, Vieta E, Colom F, Reinares M, Benabarre A, et al. Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. Psychother Psychosom 2002;71:39-46.
30. Pukrop R, Matuschek E, Ruhrmann S, Brockhaus-Dumke A, Tendolkar I, Bertsch A, et al. Dimensions of working memory dysfunction in schizophrenia. Schizophr Res 2003;62:259-268.
34. Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Hum Psychopharmacol 2007;22:445-454.
36. Yi Z, Fan X, Wang JJ, Liu D, Freudenreich O, Goff D, et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res 2012;200:79-82.
39. Schuepbach D, Egger ST, Boeker H, Duschek S, Vetter S, Seifritz E, et al. Determinants of cerebral hemodynamics during the Trail Making Test in schizophrenia. Brain Cogn 2016;109:96-104.
40. Grissom RJ. Probability of the superior outcome of one treatment over another. J Appl Psychol 1994;79:314-316.
46. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Fard L. Metaanalysis of cognitive performance in drug-naïve patients with schizophrenia. Schizophr Res 2014;158:156-162.
47. Kuha A, Tuulio-Henriksson A, Eerola M, Perälä J, Suvisaari J, Partonen T, et al. Impaired executive performance in healthy siblings of schizophrenia patients in a population-based study. Schizophr Res 2007;92:142-150.
51. Harvey PD. The genetics of cognitive impairment in schizophrenia. Psychiatry (Edgmont) 2008;5:65-67.
52. Puig MV, Gener T. Serotonin modulation of prefronto-hippocampal rhythms in fealth and disease. ACS Chem Neurosci 2015;6:1017-1025.
53. Logue SF, Gould TJ. The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition. Pharmacol Biochem Behav 2014;123:45-54.
57. Sevy S, Kay SR, Opler LA, van Praag HM. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 1990;178:642-648.
58. Mathews SB, Arnold SE, Epperson CN. Hospitalization and cognitive decline: can the nature of the relationship be deciphered? Am J Geriatr Psychiatry 2014;22:465-840.
60. Deutch AY, Noghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, et al. Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991;4:121-156.
61. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.